OXURION to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference januari 4, 20220OpmerkingenEN Read More
Jaarverslag 2021 (officiële ESEF-versie) december 30, 20210OpmerkingenJaarverslag 2021 (officiële ESEF-versie)Read More
Annual report 2021 (official ESEF version) december 30, 20210OpmerkingenAnnual report 2021 (official ESEF version)Read More
Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA december 30, 20210OpmerkingenEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA november 30, 20210OpmerkingenEN NL Read More
OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures november 22, 20210OpmerkingenEN Read More
First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrations of THR-149 versus aflibercept for Treatment of Diabetic Macular Edema (DME) november 15, 20210OpmerkingenEN Read More
Oxurion NV Announces Initiation of Equity Analyst Coverage by H.C. Wainwright with a “Buy” Recommendation november 4, 20210OpmerkingenEN Read More
Information on the Total Number of Voting Rights (Denominator) following conversion notices NEGMA november 3, 20210OpmerkingenEN NL Read More
Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment of Diabetic Macular Edema (DME) oktober 13, 20210OpmerkingenEN Read More
Positive Phase 2 Part A THR-149 data shared at the America Society of Retina Specialists (ASRS) Annual Scientific Meeting oktober 11, 20210OpmerkingenEN Read More
OXURION to Present at the Lytham Partners Fall 2021 Investor Conference oktober 5, 20210OpmerkingenEN Read More
OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME) september 30, 20210OpmerkingenEN Read More
OXURION to Present Clinical and Pre-Clinical Data at Upcoming EURETINA 2021 Virtual Congress september 8, 20210OpmerkingenEN Read More
Oxurion NV – Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal augustus 17, 20210OpmerkingenEN Read More
